欢迎访问《现代生物医学进展》编辑部！

目的：研究甲亢低骨量患者131I治疗后干预治疗的效果。方法：对100 例甲亢低骨量患者，随机分为两组：A 组50 例，131I治疗后口服钙尔奇D 及罗盖全治疗；B 组50 例，131I 治疗后骨质自然恢复。另设C 组50 例为正常对照组。于131I治疗前、治疗后3、 6 及12 个月测定A、B 两组骨密度（BMD），观察其骨质变化并评价治疗效果。结果：（1）A 组随治疗时间延长BMD 逐渐升高，具有一定的规律性，腰椎（L2-4）骨密度3 个月提高明显（t= -2.111，P=0.04）且12 个月时达到与C 组无统计学差异（t= -2.290，P=0. 202）。（2）B组3 个月时腰椎BMD 有所降低，12 个月时升高明显（股骨颈t= -2.327，P=0.043；腰椎（L2-4）t= -2.798，P=0.000）。（3） 6 个月时两组腰椎骨密度改善幅度出现统计学差异（t= -2.416，P=0.018），12 个月时差异显著(t= -3.259，P=0.002)。结论：131I联合钙尔奇D 与罗盖全治疗甲亢低骨量患者，其恢复时间及疗效均用131I 治疗，能有效防止骨量的进一步下降及减少骨质疏松症的发生。

英文摘要:

Objective:To investigate the effect of intervention therapy in patients of hyperthyroidism with low bone mass after 131I treatment.Methods:100 cases of hyperthyroidism patients with low bone mass, were randomly divided into two groups: 50 cases in group A, taking Caltrate D and Rocaltrol after 131I treatment; 50 cases in group B, bone natural recovery after 131I treatment. Another 30 cases in group C as normal control group. Before 131I treatment and after 3, 6 and 12 months, groups A and B were measured to observe the changes of bone mineral density (BMD) and evaluate the effect of intervention therapy.Results:(1) Group A: the BMD increased gradually and had a regular change. The lumbar vertebra (L2-4) reached to the level which there was no significant difference compared with that of group C after 12 months treatment (P=0.202>0.05). (2) Group B: the L2-4 had little decrease 3 months later, but increased evidently after 12 months (femoral neck: P=0.043; L2-4: P=0.000).(3) The changing extent of the L2-4 of these two groups appeared significant difference after 6 months (t= -2.416, P=0.018) and the disparity was more evident after 12 months (t= -3.259, P=0.002).Conclusion:The recovery time and curative effect of using 131I combined with Caltrate D and Rocaltrol is superior to using the single 131I treatment. The combined cure can effectively prevent further decrease in bone mass and reduce the occurrence of osteoporosis.

View Full Text View/Add Comment Download reader